The Food and Drug Administration is making moves to spur development of generic and cheaper opioids that are difficult to abuse.

The agency released new regulatory guidance on Tuesday aimed at helping drugmakers develop these products much easier. While there are already some abuse-deterrent painkillers on the market, they are only brand name drugs that are more expensive than a generic.